The meta-analysis results confirmed that the combination of zoledronic acid and CKI is more effective in treating bone cancer pain than using zoledronic acid alone (OR = 3.43, 95% CI: 2.51–4.67, P < 0.0001). Here, CHKA is linked to bone cancer.